Drugs in Dev. Ophthalmology
Phase I/ Phase II
Australia 
Lead Product(s) : Sozinibercept,Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Opthea Reports Positive Phase 2a Trial Results of OPT-302 in Diabetic Macular Edema
Details : The trial met the prespecified primary efficacy endpoint with 52.8% of patients (95% CI 41-64%) achieving ≥ 5 letters gain in Best Corrected Visual Acuity (BCVA) at week 12.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 06, 2020
Lead Product(s) : Sozinibercept,Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sozinibercept,Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Overall safety profile of OPT-302 combination therapy has continued to be favorable and has now shown consistent tolerability alone or in combination with anti-VEGF-A standard of care therapy across two eye indications.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 27, 2020
Lead Product(s) : Sozinibercept,Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sozinibercept,Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Opthea Completes Patient Dosing in Phase 2a DME Trial
Details : Opthea completed patient dosing and all follow-up week 12 patient visits in the Phase 2a trial evaluating the safety and efficacy of OPT-302 administered in combination with aflibercept.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 30, 2020
Lead Product(s) : Sozinibercept,Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAM-101
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Massachusetts Eye and Ear Infirmary | Oregon Health and Science University | University of Michigan | Duke University | Stanford University | University of Minnesota
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 30, 2018
Lead Product(s) : CAM-101
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Massachusetts Eye and Ear Infirmary | Oregon Health and Science University | University of Michigan | Duke University | Stanford University | University of Minnesota
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 11, 2018
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
